5月6日 - ** 生物技术公司Oruka Therapeutics ORKA.O的股价在盘前交易中上涨2.83%，至70.90美元
** 该公司与HalozymeHALO.O 签署全球合作协议，将 利用Hypercon技术开发银屑病治疗药物
** 银屑病是一种慢性皮肤病，因免疫系统过度活跃而导致皮肤出现红色鳞屑斑块
** 该公司表示，Oruka将把Hypercon技术与其领先的实验性药物ORKA-001相结合，以减少给药频率
** 该技术可实现更小的注射剂量，有望提升患者用药便利性——ORKA
** 协议包含预付款、里程碑付款及向Halozyme支付的专利使用费，具体条款未披露 - ORKA
** 截至上一交易日收盘，该公司股价年内涨幅约达两倍
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.